ALT News and Press, Altimmune Inc. From 06/24/24

2024-06-24 04:36:47 ET Altimmune (NASDAQ: ALT) stock price drifted upwards on Monday amid optimism that it will become a leading player in the weight loss industry. It rose by over 2%, meaning that it has soared by over 25% from the lowest point last week. Pemvidutide hopes rise ...

2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the r...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 investing in Altimmune stock or options between December 1...

GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated...

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2 nd Annual Virtual Obesity Investo...

GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at t...

2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...

2024-06-12 12:33:43 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...

Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) comp...